Key Developments: Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

11:35am EDT
Price Change (% chg)

€-0.10 (-0.87%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

AstraZeneca PLC announces strategic respiratory transaction with Almirall SA
Wednesday, 30 Jul 2014 02:02am EDT 

AstraZeneca PLC:Says agreement to transfer to the company the rights to Almirall's respiratory franchise for an initial consideration of $875 mln on completion, and up to $1.22 bln in development, launch, and sales-related milestones.Says it will own the rights for the development and commercialisation of Almirall's existing respiratory business, including rights to revenues from Almirall's existing partnerships, as well as its pipeline of investigational therapies.Under the agreement, Almirall Sofotec, an Almirall subsidiary focused on the development of devices, will also transfer to AstraZeneca.  Full Article

Almirall announces closing and payment of corporate bonds
Thursday, 27 Mar 2014 05:14am EDT 

Almirall SA:Closes issuance of 4.625 percent senior notes in amount of 325 million euros due 2021.Notes distributed among qualified investors.Joint global coordinators and bookrunners were Deutsche Bank AG, London Branch and Banco Bilbao Vizcaya Argentaria, with Nomura International plc and Banca March as joint bookrunners and Santander, CaixaBank and Societe Generale as co-managers.  Full Article

Almirall completes senior notes pricing; reveals credit rating by S&P
Wednesday, 19 Mar 2014 01:09pm EDT 

Almirall SA:Completes pricing of senior notes of 325 million euros due in 2021.Yearly fixed rate coupon of 4.625 percent, payable semi-annually.Standard & Poor's has issued corporate rating on company at BB-.  Full Article

Moody's assigns first time Ba3 CFR to Almirall SA; outlook stable
Tuesday, 18 Mar 2014 08:45am EDT 

Almirall SA:Moody's Investors Service has assigned Ba3 corporate family rating (CFR) and Ba3-PD probability of default rating (PDR) to Almirall.Moody's has assigned (P)Ba3 rating to proposed 325 million euro senior unsecured notes maturing in 2021.Outlook on ratings is stable.This is first time Moody's has assigned rating to company.  Full Article

Almirall SA to issue senior notes
Monday, 17 Mar 2014 03:03am EDT 

Almirall SA:To issue senior notes in maximum nominal amount of 325 million euros.Maturity in 2021.To be offered to qualified institutional buyers under Rule 144A of United States Securities Act of 1933.  Full Article

Almirall SA announces approval of 375 mln bond issuance
Friday, 7 Mar 2014 09:52am EST 

Almirall SA:To issue bonds of 375 million euros.  Full Article

Almirall SA announces proposal not to pay dividends
Monday, 24 Feb 2014 02:11am EST 

Almirall SA:To submit to the shareholders for approval a proposal not to pay dividends.The general shareholders' meeting to be held on May 9.  Full Article

Almirall SA to propose issuance of bonds-Reuters
Thursday, 30 Jan 2014 12:22pm EST 

Almirall SA:Calls an extraordinary meeting on Mar. 7 to submit to the shareholders for approval a bond issuance in the maximum amount of 374 million euros-Reuters.  Full Article

Goldman Sachs places five percent of Almirall SA at 11.75 euros per share-Reuters
Thursday, 23 Jan 2014 04:23am EST 

Almirall SA:Goldman Sachs places a five percent stake in Almirall SA belonging to Grupo Plafin at 11.75 euros per share-Reuters.It also said the placement, carried out through an accelerated book building, was worth 102 million euros.  Full Article

Almirall SA completes acquisition of Aqua Pharmaceuticals
Thursday, 2 Jan 2014 02:27am EST 

Almirall SA:Says it has completed the acquisition of Aqua Pharmaceuticals.Says the initial agreement of the transaction was announced on Dec. 17, 2013.Says Aqua Pharmaceuticals' current product portfolio is linked to acne, atopic dermatitis and keratosis actinic, among other dermatological specialties.  Full Article

Almirall says in deal with Astrazeneca over respiratory business

MADRID, July 30 - Spain's Almirall on Wednesday said it had reached a deal to transfer to Astrazeneca the rights of its respiratory franchise for an initial $875 million. (Reporting by Julien Toyer; Editing by Tracy Rucinski)

Search Stocks